Beneficial effects of renal sympathetic denervation on cardiovascular inflammation and remodeling in essential hypertension

Clinical Research in Cardiology

Volumn 104, Issue 2, 2015, Pages 175-184

  Dörr, Oliver ^a   Liebetrau, Christoph ^b   Möllmann, Helge ^b   Mahfoud, Felix ^c,d   Ewen, Sebastian ^c   Gaede, Luise ^b   Troidl, Christian ^b   Hoffmann, Jedrzej ^b   Busch, Nikolai ^a   Laux, Gerald ^a   Wiebe, Jens ^a   Bauer, Timm ^a   Hamm, Christian ^a,b   Nef, Holger ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b Kerckhoff Heart and Thorax Center ^*  (Germany)

^c SAARLAND UNIVERSITY   (Germany)

^d Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

Hypertension; Inflammation; Remodeling; Renal denervation

Indexed keywords

ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; CHOLESTEROL; GELATINASE A; GELATINASE B; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRIACYLGLYCEROL; BIOLOGICAL MARKER; CYTOKINE;

AGED; ARTICLE; CARDIOVASCULAR INFLAMMATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTENSION; KIDNEY DENERVATION; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RENAL SYMPATHETIC DENERVATION; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; VASCULAR REMODELING; BLOOD; CLINICAL TRIAL; COMPLICATION; HEART VENTRICLE REMODELING; INNERVATION; KIDNEY; LONGITUDINAL STUDY; MYOCARDITIS; PROCEDURES; SURGERY; SYMPATHECTOMY; TREATMENT OUTCOME;

AGED; BIOLOGICAL MARKERS; CYTOKINES; FEMALE; HUMANS; HYPERTENSION; KIDNEY; LONGITUDINAL STUDIES; MALE; MYOCARDITIS; SYMPATHECTOMY; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 84925491615     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-014-0773-4     Document Type: Article

References (51)

1. Task force for the management of arterial hypertension of the European Society of Cardiology (2007) Guidelines for the management of arterial hypertension. Eur Heart J 28:1462–1536
2. Mendall MA, Patel P, Asante M, Ballam L, Morris J, Strachan DP, Camm AJ, Northfield TC (1997) Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart 78:273–277
3. Furumoto T, Saito N, Dong J, Mikami T, Fujii S, Kitabatake A (2002) Association of cardiovascular risk factors and endothelial dysfunction in Japanese hypertensive patients: implications for early athero- sclerosis. Hypertens Res 25:475–480
4. Böhm M, Voors A, Ketelslegers JM, Schirmer SH, Turgonyi E, Bramlage P, Zannad F (2011) Biomarkers: optimizing treatment guidance in heart failure. Clin Res Cardiol 100:973–981
5. Breda L, Di Marzio D, Giannini C, Gaspari S, Nozzi M, Scarinci A, Chiarelli F, Mohn A (2013) Relationship between inflammatory markers, oxidant–antioxidant status and intima-media thickness in prepubertal children with juvenile idiopathic arthritis. Clin Res Cardiol 102:63–71
6. Fernandez-Real JM, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J, Ricart W (2001) Circulating interleukin-6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 86:1154–1159
7. Lok D, Lok S, de la Porte PBA, Badings E, Lipsic E, van Wijngaarden J, de Boer R, Dvan Veldhuisen DJ, van der Meer P (2013) Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol 102:103–111
8. Fassbach M, Schwartzkopff B (2005) Elevated serum markers for collagen synthesis in patients with hypertrophic cardiomyopathy and diastolic dysfunction. Z Kardiol 94:328–335
9. Intengan HD, Schiffrin EL (2000) Structure and mechanical properties of resistance arteries in hypertension. Role of adhesion molecules and extracellular matrix determinants. Hypertension 36:312–318
10. Li-Saw-Hee FL, Edmunds E, Blann AD, Beevers DG, Lip GY (2000) Matrix metalloproteinase-9 and tissue inhibitor metallopro- teinase-1 levels in essential hypertension. Relation- ship to left ventricular mass and anti-hypertensive therapy. Int J Cardiol 75:43–47
11. Laurent S (1995) Arterial wall hypertrophy and stiffness in essential hypertensive patients. Hypertension 26:355–362
12. Lindsay M, Maxwell P, Dunn FG (2002) TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 40:136–141
13. Madhavan S, Ooi WL, Cohen H, Alderman MH (1994) Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 23:395–401
14. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM, American Heart Association Professional Education Committee (2008) Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 117:510–526
15. Lloyd-Jones D, Adams R, Carnethon M (2009) Heart disease and stroke statistics—2009 update: a report from the American heart association statistics committee and stroke statistics subcommittee. Circulation 119:480–486
16. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J (2005) Global burden of hypertension: analysis of worldwide data. Lancet 365:217–223
17. Kopp UC, Cicha MZ, Smith LA, Mulder J, Hökfelt T (2007) Renal sympathetic nerve activity modulates afferent renal nerve activity by PGE2-dependent activation of alpha1- and alpha2-adrenoceptors on renal sensory nerve fibers. Am J Physiol Regul Integr Comp Physiol 293:561–572
18. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH (2002) Sympathetic nerve activity in end-stage renal disease. Circulation 106:1974–1979
19. Sobotka PA, Mahfoud F, Schlaich MP, Hoppe UC, Böhm M, Krum H (2011) Sympatho-renal axis in chronic disease. Clin Res Cardiol 100(12):1049–1057
20. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M (2009) Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373:1275–1281
21. Symplicity HTN-2 Investigators (2010) Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 376:1903–1909
22. Mendelsohn FO (2014) Does complete renal denervation translate into superior clinical outcomes? Lessons learned from denervation of accessory renal arteries. Clin Res Cardiol 103:681–683
23. Patel HC, Dhillon PS, Mahfoud F, Lindsay AC, Hayward C, Ernst S, Lyon AR, Rosen SD, di Mario C (2014) The biophysics of renal sympathetic denervation using radiofrequency energy. Clin Res Cardiol 103(5):337–344
24. Vogel B, Kirchberger M, Zeier M, Stoll F, Meder B, Saure D, Andrassy M, Mueller OJ, Hardt S, Schwenger V, Strothmeyer A, Katus HA, Blessing E (2014) Renal sympathetic denervation therapy in the real world: results from the Heidelberg registry. Clin Res Cardiol 103(2):117–124
25. Bhatt DL, Kandzari DE, O’Neill WW, SYMPLICITY HTN-3 Investigators (2014) A controlled trial of renal denervation for resistant hypertension. N Engl J Med 370(15):1393–1401. doi:10.1056/NEJMoa1402670
26. Dörr O, Liebetrau C, Möllmann H, Achenbach S, Sedding D, Szardien S, Willmer M, Rixe J, Troidl C, Elsässer A, Hamm C, Nef HM (2013) Renal sympathetic denervation does not aggravate functional or structural renal damage. J Am Coll Cardiol 61:479–480
27. Dörr O, Liebetrau C, Möllmann H, Gaede L, Troidl C, Rixe J, Hamm C, Nef H (2014) Soluble fms-like tyrosine kinase-1 and endothelial adhesion molecules (intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1) as predictive markers for blood pressure reduction after renal sympathetic denervation. Hypertension 63(5):984–990
28. Mahfoud F, Ukena C, Schmieder RE, Cremers B, Rump LC, Vonend O, Weil J, Schmidt M, Hoppe UC, Zeller T, Bauer A, Ott C, Blessing E, Sobotka PA, Krum H, Schlaich M, Esler M, Böhm M (2013) Response to letter regarding article, “ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension”. Circulation 128:132–140
29. Brasier AR, Recinos A III, Eledrisi MS (2002) Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 22:1257–1266
30. Sliwa K, Ojji D, Bachelier K, Böhm M, Damasceno A, Stewart S (2014) Hypertension and hypertensive heart disease in African women. Clin Res Cardiol 103(7):515–523
31. Schiffrin EL, Touyz RM (2004) From bedside to bench to bedside: role of renin- angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. Am J Physiol Heart Circ Physiol 287:H435–H446
32. Touyz RM, Schiffrin EL (2004) Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol 122:339–352
33. Schiffrin EL (2005) Vascular endothelin in hypertension. Vasc Pharmacol 43:19–29
34. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A (1994) The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 331:417–424
35. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997) Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973–976
36. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH (1998) Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98:731–733
37. Chae CU, Lee RT, Rifai N, Ridker PM (2001) Blood pressure and inflammation in apparently healthy men. Hypertension 38:399–403
38. Mitrovic V, Klein HH, Krekel N, Kreuzer J, Fichtlscherer S, Schirmer A, Paar WD, Hamm CW (2005) Influence of the angiotensin converting enzyme inhibitor ramipril on high-sensitivity C-reactive protein (hs-CRP) in patients with documented atherosclerosis. Z Kardiol 94(5):336–342
39. Engström G, Janzon L, Berglund G, Lind P, Stavenow L, Hedblad B, Lindgärde F (2002) Blood pressure increase and incidence of hypertension in relation to inflammation-sensitive plasma proteins. Arterioscler Thromb Vasc Biol 22:2054–2058
40. Dollery CM, McEwan JR, Henney AM (1995) Matrix metalloproteinases and cardiovascular disease. Circ Res 77:863–868
41. Weber KT, Sun Y, Guarda E, Katwa LC, Ratajska A, Cleutjens JP, Zhou G (1995) Myocardial fibrosis in hypertensive heart disease: an overview of potential regulatory mechanisms. Eur Heart J 16(suppl C):24–28
42. Galis ZS, Sukluva GK, Lark MW, Libby P (1994) Increased expression of matrix metalloproteinases and matrix degrading activity in vulner- able regions of human atherosclerotic plaques. J Clin Invest 94:2493–2503
43. Laviades C, Varo N, Fernández J, Mayor G, Gil MJ, Monreal I, Díez J (1998) Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 98:535–540
44. Picard F, Brehm M, Fassbach M, Pelzer B, Scheuring S, Küry P, Strauer BE, Schwartzkopff B (2006) Increased cardiac mRNA expression of matrix metalloproteinase-1 (MMP-1) and its inhibitor (TIMP-1) in DCM patients. Clin Res Cardiol 95(5):261–269
45. Brilla CG, Moderer S, Salge U, Heidmann HH (1994) Collagenolytic activity in left ventricular endomyocardial biopsies of patients with hypertensive heart disease or hypertrophic cardiomyopathy. Circulation 90(suppl I):I-264
46. Li-Saw-Hee FL, Edmunds E, Blann AD, Beevers DG, Lip GY (2000) Matrix metalloproteinase-9 and tissue inhibitor metallopro- teinase-1 levels in essential hypertension. Relation- ship to left ventricular mass and anti-hypertensive therapy. Int J Cardiol 75:43–47
47. Intengan HD, Schiffrin EL (2000) Structure and mechanical properties of resistance arteries in hypertension. Role of adhesion molecules and extracellular matrix determinants. Hypertension 36:312–318
48. Mancia G, Parati G (2004) Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: a meta-analysis. J Hypertens 22:435–445
49. Sun M, Chen M, Dawood F, Zurawska U, Li JY, Parker T, Kassiri Z, Kirshenbaum LA, Arnold M, Khokha R, Liu PP (2007) Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dys- function after pressure overload state. Circulation 115:1398e407
50. Swynghedauw B (1999) Molecular mechanisms of myocardial remodeling. Physiol Rev 79:215–262
51. Radauceanu A, Ducki C, Virion JM, Rossignol P, Mallat Z, McMurray J, Veldhuisen DJ, Tavazzi L, Mann DL, Capiaumont-Vin J, Li M, Hanriot D, Zannad F (2008) Extracellular Matrix Turnover and Inflammatory Markers Independently Predict Functional Status and Outcome in Chronic Heart Failure. J Cardiac Fail 14:467–474